Soo Han Bae

List of Publications by Year
in descending order

35 papers	8,089 citations	361413 20 h-index	361022 35 g-index
35 all docs	35 docs citations	35 times ranked	17875 citing authors

#	Article	IF	Citations
1	A GLPâ€1/GLPâ€2 receptor dual agonist to treat NASH: Targeting the gutâ€liver axis and microbiome. Hepatology, 2022, 75, 1523-1538.	7.3	29
2	PERK prevents hepatic lipotoxicity by activating the p62-ULK1 axis-mediated noncanonical KEAP1-Nrf2 pathway. Redox Biology, 2022, 50, 102235.	9.0	12
3	Lysosomal Ca2+-mediated TFEB activation modulates mitophagy and functional adaptation of pancreatic Î²-cells to metabolic stress. Nature Communications, 2022, 13, 1300.	12.8	28
4	Interplay between Saturated Free Fatty Acids and mmLDL Induces Inflammation in LPS-stimulated Macrophages. Korean Circulation Journal, 2021, 51, 81.	1.9	2
5	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 582	9.1	1,430
6	Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity. Autophagy, 2020, 16, 86-105.	9.1	41
7	Ezetimibe ameliorates lipid accumulation during adipogenesis by regulating the AMPKâ€“mTORC1 pathway. FASEB Journal, 2020, 34, 898-911.	0.5	10
8	SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity. Autophagy, 2020, 16, 1949-1973.	9.1	100
9	Genetic and Chemical Effects on Somatic and Germline Aging. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-2.	4.0	2
10	Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?. Clinical and Molecular Hepatology, 2020, 26, 577-578.	8.9	1
11	All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Yonsei Medical Journal, 2020, 61, 762.	2.2	6
12	NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimerâ€™s models. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12516-12523.	7.1	132
13	Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity. Free Radical Biology and Medicine, 2019, 137, 143-157.	2.9	17
14	Implantable Vascularized Liver Chip for Crossâ€Validation of Disease Treatment with Animal Model. Advanced Functional Materials, 2019, 29, 1900075.	14.9	28
15	Inactivation of Sirtuin2 protects mice from acetaminophen-induced liver injury: possible involvement of ER stress and S6K1 activation. BMB Reports, 2019, 52, 190-195.	2.4	14
16	The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition. Frontiers in Endocrinology, 2018, 9, 539.	3.5	6
17	CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes. PLoS ONE, 2018, 13, e0206152.	2.5	25
18	TPT1 (tumor protein, translationally-controlled 1) negatively regulates autophagy through the BECN1 interactome and an MTORC1-mediated pathway. Autophagy, 2017, 13, 820-833.	9.1	32

#	Article	IF	Citations
19	Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy, 2017, 13, 1767-1781.	9.1	152
20	The hypertension drug, verapamil, activates Nrf2 by promoting p62-dependent autophagic Keap1 degradation and prevents acetaminophen-induced cytotoxicity. BMB Reports, 2017, 50, 91-96.	2.4	31
21	Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radical Biology and Medicine, 2016, 99, 520-532.	2.9	62
22	p62/SQSTM1 is required for the protection against endoplasmic reticulum stress-induced apoptotic cell death. Free Radical Research, 2016, 50, 1408-1421.	3.3	19
23	SESN2/sestrin2 suppresses sepsis by inducing mitophagy and inhibiting NLRP3 activation in macrophages. Autophagy, 2016, 12, 1272-1291.	9.1	218
24	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
25	p62 prevents carbonyl cyanide m-chlorophenyl hydrazine (CCCP)-induced apoptotic cell death by activating Nrf2. Biochemical and Biophysical Research Communications, 2015, 464, 1139-1144.	2.1	20
26	The antioxidant function of sestrins is mediated by promotion of autophagic degradation of Keap1 and Nrf2 activation and by inhibition of mTORC1. Free Radical Biology and Medicine, 2015, 88, 205-211.	2.9	115
27	PF-4708671, a specific inhibitor of p70 ribosomal S6 kinase 1, activates Nrf2 by promoting p62-dependent autophagic degradation of Keap1. Biochemical and Biophysical Research Communications, 2015, 466, 499-504.	2.1	17
28	Fenofibrate activates Nrf2 through p62-dependent Keap1 degradation. Biochemical and Biophysical Research Communications, 2015, 465, 542-547.	2.1	27
29	Concerted action of p62 and Nrf2 protects cells from palmitic acid-induced lipotoxicity. Biochemical and Biophysical Research Communications, 2015, 466, 131-137.	2.1	27
30	Sestrins Activate Nrf2 by Promoting p62-Dependent Autophagic Degradation of Keap1 and Prevent Oxidative Liver Damage. Cell Metabolism, 2013, 17, 73-84.	16.2	415
31	Study of the Signaling Function of Sulfiredoxin and Peroxiredoxin III in Isolated Adrenal Gland. Methods in Enzymology, 2013, 527, 169-181.	1.0	2
32	Feedback Control of Adrenal Steroidogenesis via H2O2-Dependent, Reversible Inactivation of Peroxiredoxin III in Mitochondria. Molecular Cell, 2012, 46, 584-594.	9.7	149
33	Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology, 2011, 53, 945-953.	7.3	77
34	Sestrin 2 Is Not a Reductase for Cysteine Sulfinic Acid of Peroxiredoxins. Antioxidants and Redox Signaling, 2009, 11, 739-745.	5.4	92
35	Induction of Sulfiredoxinviaan Nrf2-Dependent Pathway and Hyperoxidation of Peroxiredoxin III in the Lungs of Mice Exposed to Hyperoxia. Antioxidants and Redox Signaling, 2009, 11, 937-948.	5.4	50